Replimune (REPL) Shares Tank 45% After Company Says No Pathway Identified For Lead Drug RP1, Securities Class Action Pending - Hagens Berman

REPL Investors with Losses Encouraged to Contact the Firm Before Sept. 22nd Deadline

SAN FRANCISCO, Sept. 18, 2025 /PRNewswire/ -- On September 18, 2025, investors in Replimune Group, Inc. (NASDAQ: REPL) saw the price of their shares crater about 45% during intraday trading after the company announced that it completed a Type A meeting with the FDA on September 16 to discuss its Biologics License Application ("BLA") for lead drug candidate RP1 but "a path forward under the accelerated approval pathway has not been determined." 

Read more at prnewswire.com